TY - JOUR
T1 - Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2
T2 - Results of an European Experts Panel
AU - Gridelli, C.
AU - Ardizzoni, A.
AU - Le Chevalier, T.
AU - Manegold, C.
AU - Perrone, F.
AU - Thatcher, N.
AU - van Zandwijk, N.
AU - Di Maio, M.
AU - Martelli, O.
AU - De Marinis, F.
PY - 2004/3
Y1 - 2004/3
N2 - Background: Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC), but its benefit seems limited to fit patients with a performance status (PS) of 0 or 1. For PS2 patients, there is no consensus on standard treatment. With the aims of reviewing the evidence supporting each of these therapeutic options, possibly reaching a consensus for treatment of PS2 patients affected by advanced NSCLC in clinical practice, and suggesting the priorities for clinical research in this field, an European Experts Panel took place in Avellino, Italy in April 2003. Results and conclusions: On the basis of current evidence, chemotherapy treatment appears justified for patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative options. Stronger evidence is expected from new clinical research specifically focused on PS2 patients. Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients.
AB - Background: Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC), but its benefit seems limited to fit patients with a performance status (PS) of 0 or 1. For PS2 patients, there is no consensus on standard treatment. With the aims of reviewing the evidence supporting each of these therapeutic options, possibly reaching a consensus for treatment of PS2 patients affected by advanced NSCLC in clinical practice, and suggesting the priorities for clinical research in this field, an European Experts Panel took place in Avellino, Italy in April 2003. Results and conclusions: On the basis of current evidence, chemotherapy treatment appears justified for patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative options. Stronger evidence is expected from new clinical research specifically focused on PS2 patients. Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients.
KW - Advanced disease
KW - Chemotherapy
KW - Consensus
KW - Non-small-cell lung cancer
KW - Performance status 2
UR - http://www.scopus.com/inward/record.url?scp=11144357752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144357752&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdh087
DO - 10.1093/annonc/mdh087
M3 - Article
C2 - 14998843
AN - SCOPUS:11144357752
VL - 15
SP - 419
EP - 426
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 3
ER -